Whoa! How did you get here? This company profile is not meant to be publicly available. Research on this company is incomplete, and the overall rating has been disabled, but while you are here feel free to have a look at the info we do have.
Pharmaceuticals and diagnostics
Descendants of the founding Hoffmann and Oeri families own half of the company. Sells its products in some 180 countries.
|Roche Holding Ltd||SWI||website|
| Novartis AG
owns 33% of Roche Holding Ltd
|Roche Holding Ltd|
In 2018, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of A-.
Source: CDP (2018)
This company received a score of 76.3/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
Source: Newsweek (2017)
This company received an S&P Global ESG Score of 89/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 7 Feb 2021). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2021)
In 2018, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of B.
Source: CDP (2018)
Thousands of patients have suffered and have filed lawsuits against Roche Pharmaceuticals, the manufacturer of name-brand Accutane, a drug used to treat severe acne, but which comes with high risks of complications, including birth defects and serious gastrointestinal side effects. So far, the company has paid out more than $53 million to resolve the cases.
Source: Drug Watch (2012)
Public Eye Awards are given to companies with the worst record in terms of environmental pollution and human rights violations. Over 90% of China's 10,000 annual organ transplants use organs from executed prisoners. Roche makes the drug Cell Cept, which prevents the rejection of transplanted organs. Roche markets the drug in China despite the country's unethical transplantation practices. [Listed under Information due to age of report]
Source: Berne Declaration (2010)
Roche was listed by Multinational Monitor magazine as one of the ten worst companies of 1991 for its marketing of its Versed sedative. (Noted here as 'additional information only' due to age of report).
Source: McSpotlight (1992)
Named one of Multinational Monitor's '10 Worst Corporations of 2005'. [Listed under Information due to age of report]
Source: Multinational Monitor (2005)
Named one of Multinational Monitor's '10 Worst Corporations of 2008'. (Listed under information due to age of report)
Source: Multinational Monitor (2008)
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)
This company received the tenth highest score in the Access to Medicine Index 2018, a ranking of the world's 20 largest pharmaceutical companies on their efforts to increase access to medicine in developing countries.
Source: Access to Medicine Index (2018)
|Type||Listed Public Company|
|Revenue||52.3 billion USD (2010)|
|Subsidiaries||Roche Products Pty Ltd|